Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Select Medical Holdings (SEM) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Select Medical Holdings (SEM) over the last 17 years, with Q2 2025 value amounting to $1.6 million.

  • Select Medical Holdings' Other Operating Expenses rose 7970000.0% to $1.6 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 5292.49%. This contributed to the annual value of $3.4 million for FY2024, which is 12437.42% up from last year.
  • As of Q2 2025, Select Medical Holdings' Other Operating Expenses stood at $1.6 million, which was up 7970000.0% from $106000.0 recorded in Q4 2024.
  • Select Medical Holdings' 5-year Other Operating Expenses high stood at $98.1 million for Q2 2021, and its period low was -$2000.0 during Q2 2024.
  • For the 5-year period, Select Medical Holdings' Other Operating Expenses averaged around $11.9 million, with its median value being $1.7 million (2021).
  • As far as peak fluctuations go, Select Medical Holdings' Other Operating Expenses tumbled by 10027.55% in 2024, and later skyrocketed by 7970000.0% in 2025.
  • Quarter analysis of 5 years shows Select Medical Holdings' Other Operating Expenses stood at $10.2 million in 2021, then tumbled by 52.03% to $4.9 million in 2022, then crashed by 93.72% to $307000.0 in 2023, then tumbled by 65.47% to $106000.0 in 2024, then skyrocketed by 1401.89% to $1.6 million in 2025.
  • Its Other Operating Expenses was $1.6 million in Q2 2025, compared to $106000.0 in Q4 2024 and $1.3 million in Q3 2024.